Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting
Key result
Higher pre-operative HDL-C levels were not associated with a reduced risk of MACE (HR 1.43, P=0.11) or death in patients with coronary artery disease undergoing elective CABG.
Why the study?
Are high pre-operative HDL-C levels associated with reduced cardiovascular events in patients with coronary artery disease undergoing elective CABG?
Population
1548 consecutive patients with coronary artery disease undergoing isolated first-time elective CABG at one…
Comparison
High pre-operative HDL-C levels vs Low pre-operative HDL-C levels
Design
Cohort
Follow-up
median 32 months
Authors
Discussion
Loading...
Member takes
Implication
High pre-operative HDL-C should not guide risk assessment in elective CABG; leaves open any causal role in post-operative outcomes.
Study Design
Type
Cohort (n=1,548)
Multicenter
No
Structured PICO
Are high pre-operative HDL-C levels associated with reduced cardiovascular events in patients with coronary artery disease undergoing elective CABG?
P
Population
1548 consecutive patients with coronary artery disease undergoing isolated first-time elective CABG at one institution between 2004 and 2009 (propensity matched to two cohorts of 502 patients each)
I
Intervention
High pre-operative HDL-C levels (according to ATPIII criteria)
C
Comparator
Low pre-operative HDL-C levels
O
Outcome
Cumulative survival and major adverse cardiovascular events (MACE)composite
Main Result
Effect estimate: HR 1.43
Absolute Event Rate: 32.9% vs 23.9%
p-value: p=0.11
Higher pre-operative HDL-C levels do not protect against, and may even be associated with increased, major adverse cardiovascular events in CAD patients undergoing CABG.
Cite This Study
Angeloni et al. (2013) conducted a cohort in Coronary artery disease (n=1,548). High HDL-C vs. Low HDL-C was evaluated on Major adverse cardiovascular events (MACE) (HR 1.43, p=0.11). Higher pre-operative HDL-C levels were not associated with a reduced risk of MACE (HR 1.43, P=0.11) or death in patients with coronary artery disease undergoing elective CABG.